The choice should be based on cost, tolerability rather than efficacy in HCC prevention.
Phase 3 data are insufficient to guide later lines of treatment.
Findings emphasise the importance of promoting physical activity.
Expansion would include tumors that do not meet Milan criteria but respond to locoregional therapies.
Patients with high very early recurrence risk might benefit from supplementary therapy.
Royal Marsden study finds that microscopic colitis is an important subgroup in patients with immune checkpoint inhibitor-related diarrhoea/colitis.
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation.
A predictive role for IL-27 was demonstrated in 2 large prospective cohort studies.
The latest recommendations update those published in January 2020.
Prediction of life expectancy in patients with hepatocellular carcinoma and spinal metastases.
The treatment will be available through the EAMS for unresectable hepatocellular carcinoma that has not previously been treated with systemic therapy
The Viability Testing and Transplantation of Marginal Livers trial.
This is the first time this negative interaction has been reported in hepatocellular carcinoma.
VEGF has been linked to progression, but can play a role in immunosuppression.
Meta-analysis of observational studies confirms the association.
Findings from a meta-analysis of 24 observational studies.
Analysis of incidence data from 195 countries and territories.
